Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)Thomas Bachelot, A Wroński, Jean-Louis Merot et al.|Annals of Oncology|2019Cited by 117
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognosticationDavid Miles, Hamdy Abdel Azeem, Eva Ciruelos et al.|Annals of Oncology|2021Cited by 92
Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2‐negative breast cancer patients in Israel: A registry analysisGil Bar‐Sela, Salomon M. Stemmer, Samih Yousef et al.|The Breast Journal|2020Cited by 2
Next-generation sequencing (NGS) in relapsed/refractory triple-negative breast cancer (TNBC) in Israel.Noa Ben-Baruch, Jeffrey S. Ross, Georgeta Fried et al.|Journal of Clinical Oncology|2014Cited by 1